SYRACUSE, N.Y., Aug. 1, 2018 /PRNewswire/ -- Quadrant Biosciences Inc., an emerging life science company based in Syracuse, New York, announced that its ClearEdge Brain Health Toolkit was named Best Sports Medical Technology of 2018 by Orthopedics This Week ("OTW"). The award was presented to the company at the recent American Orthopaedic Society for Sports Medicine meeting in San Diego, California. Quadrant Biosciences, which focuses on the development of functional assessment and epigenetic biomarkers, has spent several years researching and developing the ClearEdge Toolkit as a way of objectively and quantitatively assessing and monitoring indicators of brain health such as concussion. The toolkit, designed in conjunction with SUNY Upstate Medical University, was commercially released in the Fall of 2017.
Quadrant Founder and CEO Richard Uhlig expressed his great appreciation for the award, which recognizes ten products like ClearEdge that are innovative, solve a clinical need, and have the potential to improve the standard of patient care. "I am very honored to accept the Sports Technology Award from Orthopedics This Week on behalf of all of my colleagues at Quadrant who have worked tirelessly for several years to bring this vitally important product to market."
The ClearEdge Toolkit was designed to respond to the growing concern over brain health and injury and the need for more objective assessment tools. But its roots lie in a very personal experience. Five years ago, Uhlig watched as his youngest son was checked into the boards of a youth hockey game and suffered a concussion. He became frustrated with the paucity of information about the injury, and the subjective nature of its diagnosis. "It was clear that the diagnosis of the injury, and the management of recovery, were based on physician's best guess, and for a brain injury, that was unacceptable," said Uhlig. So the retired Wall Street executive proceeded to consume all of the available literature on the subject, meet with prominent researchers, clinicians, and engineers, and develop what is now the ClearEdge Toolkit.
Objectively measuring and tracking subtle changes in balance and cognitive function has utility for a number of neurological and other applications. As a result, ClearEdge has partnered with national organizations interested in regular brain health monitoring such as the the U.S. Allstar Federation (USASF) for cheerleading and dance, Team Tokey Hill Karate, and the Hall of Fame Player's Foundation. According to Uhlig, "several more partnerships" are in the works as ClearEdge continues to gain clinical adoption across the country.
Quadrant Biosciences Inc. is a Life science company involved in the development of functional assessments and epigenetic diagnostic solutions for large-scale health issues. The company participates in the Start-up NY program, a New York State economic development program. Quadrant Biosciences has also entered into collaborative research relationships with a number of institutions including SUNY Upstate Medical University and Penn State University to explore and develop novel biomarker technologies with a focus on Autism Spectrum Disorder, concussion, and Parkinson's Disease. For more information about the ClearEdge toolkit, visit www.clearedgetest.com. For information about the company, or if interested in participating in the testing, contact Quadrant Biosciences at [email protected] or visit their website at www.QuadrantBiosciences.com.
SOURCE Quadrant Biosciences Inc.